67947-08-4

Upstream product

• 501-92-8 4-(prop-2-enyl)phenol 
• 140-67-0 Estragole 

Downstream Products

• 222422-33-5 tert-butyldimethyl(4-(oxiran-2-ylmethyl)phenoxy)silane 
• 375856-67-0 4-(4-bromo-benzyl)-1-{3-[4-(tert-butyl-dimethyl-silanyloxy)-phenyl]-2-hydroxy-propyl}-piperidin-4-ol 
• 375856-65-8 1-{3-[4-(tert-butyl-dimethyl-silanyloxy)-phenyl]-2-hydroxy-propyl}-4-(4-methyl-benzyl)-piperidin-4-ol 
• 375856-66-9 1-{3-[4-(tert-butyl-dimethyl-silanyloxy)-phenyl]-2-hydroxy-propyl}-4-(4-chloro-benzyl)-piperidin-4-ol 
• 222422-32-4 (RS)-4-Benzyl-1-{3-[4-(tert-butyl-dimethyl-silanyloxy)-phenyl]-2-hydroxy-propyl}-piperidin-4-ol 
• 375856-64-7 1-(4-benzyl-piperidin-1-yl)-3-[4-(tert-butyl-dimethyl-silanyloxy)-phenyl]-propan-2-ol 
• 762244-03-1 4-benzyl-1-{3-[4-(tert-butyl-dimethyl-silanyloxy)-phenyl]-2-methoxy-propyl}-piperidine 

Relevant academic research and scientific papers

Discovery of (R)-1-[2-hydroxy-3-(4-hydroxy-phenyl)-propyl]-4-(4-methyl-benzyl)-piperidin- 4-ol: A novel NR1/2B subtype selective NMDA receptor antagonist

Starting from Ro-25-6981 as a lead compound, highly potent and selective NR1/2B subtype selective NMDA receptor antagonists, with low activity at α1 adrenergic receptors were developed.

4-HYDROXY-PIPERODINE DERIVATIVES

The present invention relates to compounds of the formula STR1 wherein x is--O--,--NH--,--CH 2--,--CH=,--CO 2--,--CONH--,--CON(lower alkyl)--,--S--and--SO 2--; R. sup.1-R. sup.4 are, independently from each other hydrogen, halogen, hydroxy, amino, nitro, lower-alkyl-sulfonylamido, 1-or 2-imidazolyl, 1-(1,2,4-triazolyl) or acetamido;R 5, R 6 are, independently from each other hydrogen, lower-alkyl, hydroxy, lower alkoxy or oxo;R. sup.7-R 10 are, independently from each other hydrogen, lower-alkyl, halogen, trifluoromethyl or lower-alkoxy;n is 0 or 1; and to pharmaceutically acceptable acid addition salts thereof. Compounds of the present invention are NMDA(N-methyl-D-aspartate)-receptor subtype selective blockers.